Hepatitis B virus X protein (HBx) plays critical roles in the pathogenesis of hepatocellular carcinoma (HCC). Here, we were interested in knowing whether the oncogene Lin28A and its homolog Lin28B are involved in the hepatocarcinogenesis mediated by HBx. We showed that the expression levels of Lin28A and Lin28B were increased in clinical HCC tissues, HepG2.2.15 cell line and liver tissues of p21-HBx transgenic mice. Interestingly, the expression levels of HBx were positively associated with those of Lin28A/Lin28B in clinical HCC tissues. Moreover, the overexpression of HBx resulted in the upregulation of Lin28A/Lin28B in hepatoma HepG2/H7402 cell lines by transient transfection, suggesting that HBx was able to upregulate Lin28A and Lin28B. Then, we examined the mechanism by which HBx upregulated Lin28A and Lin28B. We identified that the promoter region of Lin28A regulated by HBx was located at nt À 235/ À 66 that contained Sp-1 binding element. Co-immunoprecipitation showed that HBx was able to interact with Sp-1 in HepG2-X cells. Moreover, chromatin immunoprecipitation (ChIP) demonstrated that HBx could bind to the promoter of Lin28A, which failed to work when Sp-1 was silenced. Electrophoretic mobility shift assay (EMSA) further identified that HBx was able to interact with Sp-1 element in Lin28A promoter via transcription factor Sp-1. In addition, we found that c-Myc was involved in the activation of Lin28B mediated by HBx. In function, Lin28A/Lin28B played important roles in HBx-enhanced proliferation of hepatoma cells in vitro and in vivo. In conclusion, HBx activates Lin28A/Lin28B through Sp-1/c-Myc in hepatoma cells. Lin28A/Lin28B serves as key driver genes in HBx-induced hepatocarcinogenesis.
INTRODUCTION
The infection of hepatitis B virus (HBV) is closely associated with the development of hepatocellular carcinoma (HCC), 1 in which HBV X protein (HBx) plays critical and multiple roles in the pathogenesis of HCC. As an oncoprotein, HBx modulates transcription, signal transduction, cell cycle progress, apoptosis, proliferation and migration by directly or indirectly interacting with various transcription factors (such as activator protein 1, nuclear factor-kB, c-Myc, Sp-1 and ATF/CREB) or proteins of signal pathways. [2] [3] [4] Our laboratory has reported that arachidonic acid metabolism, extracellular signal-related kinases, sterol regulatory element-binding protein 1c (SREBP-1c), fatty acid synthase, 5-lipoxygenase, cyclooxygenase-2, Yes-associated protein (YAP) and long noncoding RNA highly upregulated in liver cancer (HULC) are involved in the HBx-induced hepatoma. [5] [6] [7] [8] Therapeutically, HBx is an important target for HBV-induced HCC. However, the underlying mechanisms by which HBx induces hepatocarcinogenesis remain an unsolved mystery.
Lin28A as an evolutionarily conserved RNA-binding protein is first characterized in the Caenorhabditis elegans, and plays a critical role in the developmental timing. 9 Several reports have demonstrated that Lin28A is able to bind to a crowd of mRNAs, including the mRNAs of IGF-2, Oct4 and several cell cycle-related factors, to regulate their translation. [9] [10] [11] [12] [13] In addition, Lin28A can bind to the terminal loops of the precursor of the let-7 family microRNAs and blocks their processing into mature form. 14, 15 Interestingly, Lin28A as a factor of induced pluripotent stem cells may be used to convert human somatic fibroblasts to pluripotency with Oct4, Nanog and Sox2. 16 Importantly, further evidence points that Lin28A is overexpressed in primary human tumors and human cancer cell lines and functions as an oncogene to promote malignant transformation. 11, 17, 18 In breast carcinoma cells, Lin28A promotes tumorigenic activity by suppressing let-7 maturation. 19 Lin28A is a marker for testicular germ cell tumors. 20 In human small-cell lung cancer cells, Lin28A is able to promote cell cycle progression. 21 Hepatitis C virus increases the expression of Lin28A in hepatoma cell line. 22 Lin28B as a homolog of Lin28A is first identified and characterized in human HCC. 23 Similar to Lin28A, Lin28B is a RNA-binding protein that inhibits biogenesis of let-7. However, they function to regulate let-7 by distinct mechanisms. 24 Lin28B is overexpressed in diverse cancers. 25 In addition, Lin28B is associated with advanced diseases and poor clinical outcome in HCC. 17 However, the roles of oncogene Lin28A and Lin28B in HBVassociated hepatocarcinogenesis remain unclear.
In the present study, we try to gain insight into the roles of oncogene Lin28A and Lin28B in HBx-associated HCC. Interestingly, our data show that HBx is able to upregulate Lin28A/Lin28B through transcription factor Sp-1/c-Myc, resulting in the promotion of hepatoma cell proliferation. Our finding provides new insights into the mechanism of hepatocarcinogenesis induced by HBx.
RESULTS
The expression levels of HBx are positively associated with those of Lin28A and Lin28B in HCC tissues It has been reported that the overexpression of Lin28B is associated with poor outcome of liver cancer patients. 16 However, the expression level of Lin28A in HCC is not well known. To elucidate the significance of Lin28A expression in hepatoma, we examined the levels of Lin28A in hepatoma cell lines and HCC tissues. Our data showed that the expression levels of Lin28A were significantly increased in hepatoma HepG2 and H7402 cells relative to the immortalized human liver L-O2 and Chang liver cells (Supplementary Figure S1) . Immunohistochemical staining showed that the positive rate of Lin28A was 65.52% (190/290) in HCC tissues using tissue microarray, and the cases of 4-5 scale in pathology (over 50% Lin28A-positive staining cells) were 142 out of 190 (74.74%) Lin28A-positive HCC tissues (Figure 1a ), suggesting that Lin28A may play important roles in the pathogenesis of HCC. Lin28A mRNA levels were higher in HCC tissues relative to their adjacent noncancerous hepatic tissues in 38 out of 43 pairs of samples (Po0.01, Wilcoxon's signed-rank test, Figure 1b) . Strikingly, the expression levels of HBx were positively correlated with those of Lin28A in 43 cases of clinical HCC tissues (r ¼ 0.6702, Po0.0001, Pearson's correlation, Figure 1c ), suggesting that HBx may upregulate Lin28A. It has been reported that Lin28B is overexpressed in HCC tissues. 23 We confirmed that Lin28B mRNA levels were higher in HCC tissues relative to their adjacent noncancerous hepatic tissues in 40 out of 43 pairs of samples (Po0.001, Wilcoxon's signed-rank test, Figure 1d ). However, the relationship between HBx and Lin28B in hepatoma tissues is unclear. We found that the expression levels of HBx were positively associated with those of Lin28B in the above-mentioned HCC tissues (r ¼ 0.6901, Po0.0001, Pearson's correlation, Figure 1e ). Therefore, we conclude that Lin28A/Lin28B is upregulated in HCC tissues and the expression levels of Lin28A/ Lin28B are positively associated with those of HBx in these tissues.
HBx is able to upregulate Lin28A and Lin28B in hepatoma cells and p21-HBx transgenic mice Next, we try to identify the effect of HBx on Lin28A in hepatoma cells. Our data demonstrated that the expression levels of Lin28A were higher in the HepG2.2.15 cells (integrated HBV DNA) relative to HepG2 cells. However, Lin28A was downregulated by HBx RNA interference (RNAi; Figure 2a) . Moreover, the transfection of pCH-9/3091 containing a genome-length HBV sequence resulted in the upregulation of Lin28A in HepG2 cells (Figure 2b ). Then, we examined the mRNA levels of Lin28A in the liver tissues of p21-HBx transgenic mice (C57BL/6) that developed HCC after the age of 18 months. 26 Our data showed that the levels of Lin28A were increased in p21-HBx transgenic mice compared with wild-type littermate mice (C57BL/6) ( Figure 2c) . We also observed similar results for Lin28B in HepG2.2.15 cells, pCH-9/3091-stimulated HepG2 cells and p21-HBx transgenic mice (Figure 2d ). In addition, we found that Lin28A and Lin28B were upregulated, respectively, in hepatoma HepG2/H7402 cells when the cells were transiently transfected with HBx expression plasmids (pCMV-X) in a dose-dependent manner (Figures 3a, c and e) . Meanwhile, the expression levels of Lin28A and Lin28B were reduced by HBx RNAi (Figures 3b, d and e). We further observed that the protein level of Oct4, a downstream target of Lin28A, was downregulated by Lin28A small interfering RNA (siRNA) or HBx RNAi in the above-mentioned HBx-expressing cells (Supplementary Figure S2) , supporting the fact that HBx is able to upregulate Lin28A. We conclude that HBx is able to upregulate Lin28A and Lin28B in hepatoma cells.
HBx increases the promoter activity of Lin28A To elucidate the mechanism of upregulation of Lin28A mediated by HBx, we cloned the constructs of Lin28A 5 0 -flanking region, including and þ 152/ þ 375 (pGL3-Lin28A-P5). Next, the plasmids were transiently transfected into HepG2 (or H7402) cells to assess the promoter core region of Lin28A. The luciferase reporter gene assays indicated that the pGL3-Lin28A-P2 containing fragment À 643/ þ 375 exhibited the maximum luciferase activity (Figure 4a ), suggesting that the fragment is the core region of Lin28A promoter. Then, we examined the effect of HBx on different fragments of Lin28A promoter. The results indicated that HBx was able to activate the luciferase activities of pGL3-Lin28A-P1 (Figure 4b ), pGL3-Lin28A-P2 ( Figure 4c ) and pGL3-Lin28A-P3 (Figure 4d ), respectively, but not pGL3-Lin28A-P4 (Supplementary Figure S3) . Figure 4e delineates the model of region (fragment À 235/ À 66) of Lin28A promoter that is the regulation site of HBx.
HBx activates the Lin28A/Lin28B promoter through Sp-1/c-Myc To further unravel the mechanism by which HBx activates Lin28A promoter, we predicted the transcription factor binding sites in the promoter region À 235/ À 66 using promoter analysis program TF2 SEARCH (http://www.cbrc.jp/research/db/ TFSEARCH.html). We found that there were a broad variety of different promoter elements in the promoter region À 235/ À 66, such as Sp-1 and Ap-2. It has been reported that HBx is able to transactivate Sp-1 to regulate transcription. 27 Therefore, we presumed that HBx might activate Lin28A promoter through Sp-1. Interestingly, the promoter activities of the Lin28A could be abolished by Sp-1 siRNA. Meanwhile, HBx failed to work when the Sp-1 binding site in Lin28A promoter was mutated (Figure 5a ). The same results were observed in 293T cells (Supplementary Figure S3 ). The expression of Lin28A was also downregulated by Sp-1 siRNA at the mRNA and protein levels (Figure 5b ), which is consistent with the above data. It suggests that Sp-1 may be involved in the upregulation of Lin28A mediated by HBx. Thus, we were interested in knowing whether HBx is able to interact with The HepG2 and H7402 (or HepG2-X and H7402-X) cell lines were co-transfected with pGL3-Lin28A-P1 (or pGL3-Lin28A-P2, pGL3-Lin28A-P3) and pCMV-X (or pSilencer-X), respectively. The pCMV-tag2B (or pSilencer control) vector was used as a control (referred to as HBx 0 or pSilencer-X 0). The promoter activity of Lin28A was measured by luciferase reporter gene assays. All experiments were repeated three times. Statistically significant differences are indicated: *Po0.05, **Po0.01, Student's t-test. (e) The illustration of the responsive region to HBx in Lin28A promoter. The HepG2 and 293T cell lines were co-transfected with pGL3-Lin28B-P and pCMV-tag2B, pCMV-X, control siRNA and c-Myc siRNA, respectively. The promoter activity of Lin28B was measured by luciferase reporter gene assays. All experiments were repeated three times. The relative mRNA expression levels of Lin28B were detected by qRT-PCR in HepG2-X and H7402-X cells transfected with control siRNA (or c-Myc siRNA), respectively. Statistically significant differences are indicated: *Po0.05, **Po0.01, Student's t-test.
Sp-1 in the cells. Strikingly, we found that the anti-HBx antibody was able to immunoprecipitate the Sp-1 and vice versa in HepG2-X cells (Figure 5c ), indicating that HBx is able to bind to Sp-1 directly or indirectly. As shown in Figure 5d , we observed that Lin28A promoter could be detected in the anti-HBx-immunoprecipitated candidates by chromatin immunoprecipitation (ChIP), whereas the Lin28A promoter was undetectable when the cells were treated with Sp-1 siRNA, suggesting that HBx is able to bind to the promoter region of Lin28A via Sp-1. The electrophoretic mobility shift assay (EMSA) further proved that Sp-1 element in Lin28A promoter was involved in the interaction between HBx and Lin28A promoter. The results revealed that HBx could increase the interaction of Sp-1 with the consensus sequence of Lin28A promoter in HepG2-X cells relative to HepG2 cells, whereas the interaction could be blocked when the anti-HBx antibody, anti-Sp-1 antibody or cold competitor was added into the nuclear extracts, respectively (Figure 5e Figure S4) , suggesting that HBx and Sp-1 are involved in the activation of Lin28A promoter in the complex.
It has been reported that the promoter region of Lin28B contains the binding sites of transcription factor c-Myc. 28 HBx is able to upregulate oncogenes through activating transcription factor c-Myc in human hepatoma cells. 29 Thus, we presumed that HBx may activate Lin28B promoter through c-Myc. Strikingly, we found that HBx was able to increase the promoter activities of Lin28B, whereas the enhanced activities could be abolished by c-Myc siRNA in HepG2 or 293T cells (Figure 5f ). Meanwhile, the quantitative reverse transcriptase-PCR (qRT-PCR) and western blot analysis showed that the upregulated expression of Lin28B mediated by HBx was suppressed by c-Myc siRNA (Figure 5f and Supplementary Figure S5) . Thus, we conclude that c-Myc is responsible for the upregulation of Lin28B mediated by HBx.
Lin28A/Lin28B contributes to the proliferation of hepatoma cells mediated by HBx It has been reported that HBx promotes the proliferation of hepatoma cells in a stable HBx transfection system. 30 Little is known about the function of Lin28A in the proliferation of hepatoma cells. To determine whether HBx functions through Lin28A, we performed 3-(4, 5-dimethylthiazol-2-yl) À 2, 5-diphenyltetrazolium bromide (MTT), 5-ethynyl-2 0 -deoxyuridine (EdU) and colony-formation assays. The data in vitro showed that treatment with Lin28A siRNA1 or Lin28A siRNA2 abolished the enhanced proliferation of HepG2 cells mediated by HBx, which was repeatable in the H7402/H7402-X system (Figures 6a-d) . It has been reported that Lin28B is involved in the proliferation of liver cancer cells. 31 To assess whether Lin28B is also involved in the enhanced cell proliferation mediated by HBx, we performed MTT assay. MTT indicated that treatment with Lin28B siRNA abolished the HBx-enhanced proliferation of HepG2 cells, which could be repeatable in the H7402/H7402-X system (Figure 6e ). Western blot analysis showed that the Lin28B siRNA could efficiently suppress the expression of Lin28B (Supplementary Figure 6a) . There is no significant reduction of Lin28B by treating with siRNA for Lin28A, and vice versa, suggesting that lin28A siRNA1 is specific to Lin28A, and lin28B siRNA is specific to Lin28B (Supplementary Figure 6b) . To assess whether a combined knockdown of Lin28A and Lin28B induces an additive or synergistic effect, we performed MTT assay. The data showed that downregulation of both Lin28A (30 nM) and Lin28B (30 nM) by siRNAs resulted in the similar suppressed cell proliferation compared with the downregulation of Lin28A (60 nM) or Lin28B (60 nM) alone, suggesting that a combined knockdown of Lin28A and Lin28B may induce an additive but not synergistic effect on hepatoma cell proliferation (Supplementary Figure 6c) . Based on our findings in vitro, we performed the animal transplantation assay and found that treatment with Lin28A siRNA1 abolished the enhanced growth of HepG2 cells mediated by HBx in vivo (Figures 7a-c) . Western blot analysis confirmed that the expression levels of Lin28A were downregulated in the tumor tissues from the animals, but not HBx (Supplementary Figure 7a) . Meanwhile, similar animal transplantation assay showed that Lin28B was involved in the HBx-enhanced growth of HepG2 cells as well as in vivo (Figures 7d-f) . We confirmed that the expression levels of Lin28B were significantly decreased in the Lin28B siRNAtreated groups by western blot (Supplementary Figure 7b) . We conclude that Lin28A/Lin28B contributes to the HBx-enhanced proliferation of hepatoma cells.
DISCUSSION
As an oncoprotein, HBx plays a crucial role in the development of HCC. HBx regulates a wide variety of host genes and influences gene transcription, signal transduction, cell proliferation, cell cycle progress, apoptosis, metastasis and genetic stability.
2,4,32 Lin28A and Lin28B are highly expressed in a variety of cancers, including esophagus, breast, colon, liver and ovarian cancers, and play important roles in regulating cell proliferation. 19, 23, 25, [33] [34] [35] In this study, we focused on the investigation of the function of Lin28A and its homolog Lin28B in the development of HBx-induced HCC.
To evaluate the significance of Lin28A and Lin28B in the development of HBV-associated hepatoma, we examined the relationships between HBx and Lin28A/Lin28B in clinical HCC samples. We found that the expression levels of Lin28A/Lin28B were much higher in HBV-related HCC than their adjacent noncancerous hepatic tissues. However, it has been reported that Lin28A is highly expressed in only 1 out of 22 cases of HCC tissues by RT-PCR. 36 We suppose that the highly expressed Lin28A in HCC tissues may be related to the HBV infection in liver. It is interesting to note that the expression levels of Lin28A/Lin28B were positively correlated with those of HBx in clinical HCC tissues. Accordingly, we hypothesized that HBx may upregulate Lin28A/Lin28B in the cells. Indeed, we observed that HBx upregulated Lin28A/Lin28B in hepatoma cells. Therefore, the simultaneous upregulation of Lin28A and Lin28B is HBx dependent. Thus, we conclude that Lin28A and Lin28B may be involved in the development of HBVrelated HCC.
Next, we tried to identify the underlying mechanism of upregulation of Lin28A and Lin28B mediated by HBx. To demonstrate that HBx may activate the Lin28A promoter, we identified that the region of À 643/ þ 375 was the core region of Lin28A promoter. Then, we found that HBx was able to activate the fragment À 235/ þ 375 of Lin28A promoter. Interestingly, we predicted that the region À 235/ À 66 contained the transcription factor binding sites of Sp-1, which is a member of the Sp/KLF family of transcription factors, and many genes encoding various cell growth regulatory proteins contain Sp-1 sites in their promoters. 37 Sp-1 is overexpressed in a variety of cancers, including liver, breast, colon, pancreas, bladder and prostate cancer, and plays an important role in regulating cell proliferation by modulating the expression of several cell cycle regulatory proteins. 38, 39 In this study, we found that Sp-1 was involved in the upregulation of Lin28A mediated by HBx. Next, we try to confirm that HBx is able to interact with Sp-1 in the cells. HBx can bind to TATA-binding protein (TBP) or histone deacetylase 1 (HDAC1), which are the binding proteins of Sp-1. 40, 41 We identified that HBx was able to bind to Sp-1 by co-immunoprecipitation in the cells. To detect the interaction of HBx with the promoter of Lin28A through Sp-1, we performed a ChIP assay. We observed that HBx was able to indirectly bind to the promoter of Lin28A via Sp-1. Moreover, EMSA revealed that HBx could bind to the Sp-1 consensus sequence in the Lin28A promoter through transcription factor Sp-1. Thus, we conclude that HBx is able to upregulate the expression of Lin28A through Sp-1. Next, we try to identify the mechanism by which HBx upregulates Lin28B. It has been reported that transcription factor c-Myc is involved in the activation of Lin28B promoter. 28 c-Myc is able to regulate cell growth and proliferation and exhibits a prominent role in the development of human cancers including HCC. 42 Therefore, we supposed that c-Myc may be responsible for the upregulation of Lin28B by HBx. We cloned the promoter region of Lin28B, which contains the binding sites of c-Myc. Luciferase reporter gene assay, qRT-PCR and western blot analysis support the notion that HBx is able to upregulate Lin28B through transcription factor c-Myc.
We examined the effect of Lin28A or Lin28B on HBx-enhanced cell proliferation in vitro and in vivo. We found that cell proliferation was decreased when Lin28A was downregulated by siRNA in HBx-expressing hepatoma cells. In addition, the tumor formation of hepatoma cells in nude mice was significantly inhibited by Lin28A RNAi. It suggests that Lin28A is required for the HBx-enhanced cell proliferation. Cancer stem cells have been implicated in the maintenance and progression of several types of cancer. Furthermore, HBx promotes 'stemness' in the pathogenesis of HCC by activating Oct-4, Nanog, Klf-4, b-catenin, epithelial cell adhesion molecule and epigenetic upregulation of miR-18. 43 We suppose that Lin28A, which is an induced pluripotent stem cells gene, may also be involved in the 'stemness' mediated by HBx. In addition, it has been reported that Lin28B is involved in the liver cancer cell proliferation. 31 We found that cell proliferation was decreased when Lin28B was downregulated by siRNA in hepatoma cells. Therefore, we conclude that Lin28A and Lin28B play important roles in hepatocarcinogenesis mediated by HBx. Lin28A and its homolog Lin28B as RNA-binding proteins are able to bind to a crowd of mRNAs. It has been reported that Lin28A and Lin28B inhibited the biogenesis of let-7 by distinct mechanisms. 13, 23 We found that Lin28A and Lin28B induced an additive but not synergistic effect on hepatoma cell proliferation. It suggests that both Lin28A and Lin28B are required for the HBx-induced hepatocarcinogenesis, involving regulating let-7 together. 44 However, they function through different pathways. Taken together, we conclude that Lin28A and its homolog Lin28B are important oncoproteins, which are highly expressed in HCC tissues. HBx is able to upregulate Lin28A/Lin28B through transcription factor Sp-1/c-Myc in hepatoma cells. Lin28A and its homolog Lin28B serve as key drivers in HBx-induced hepatocarcinogenesis. Thus, our finding provides new insights into the hepatocarcinogenesis mediated by HBx.
MATERIALS AND METHODS

Cell culture and tissue specimen
The human immortalized liver L-O2, Chang liver cells, human hepatoma H7402 and H7402-X (H7402 stably transfected with the HBx gene) cell lines 45, 46 were cultured in RPMI-1640 Medium (Gibco, Grand Island, NY, USA) with 10% fetal calf serum. HepG2, HepG2.2.15 (a hepatoma HepG2 cell line integrated full-length HBV DNA), HepG2-X (HepG2 stably transfected with the HBx gene) 7 and human embryonic kidney cell line 293T were cultured in Dulbecco's modified Eagle's medium (Gibco) with 10% fetal calf serum. In all, 43 pairs of HBV-related HCC and adjacent nontumorous liver tissues were collected from patients undergoing resection of HCC in Tianjin First Center Hospital (Tianjin, People's Republic of China). Informed consent was obtained from each patient and the study was approved by the Institute Research Ethics Committee at Nankai University.
Immunohistochemistry
The hepatocellular carcinoma tissue microarrays were obtained from the Xi'an Aomei Biotechnology Co., Ltd (Xi'an, China). These microarrays were composed of 290 HCC tissue samples (215 male and 75 female, average age 58 years), which included duplicate core biopsies (1 mm in diameter) from fixed, paraffin-embedded tumors. Immunohistochemical staining of samples were performed as previously reported 46 and the primary antibody of rabbit anti-Lin28A was used (Proteintech Group, Chicago, IL, USA). Based on the percentage of cells with positive nuclear and/or cytoplasmic staining, staining patterns were classified as a six-grade scale: 46 
Treatment of cultured cells
Cells were cultured in 6-well or 24-well plates for 24 h and were then transfected with plasmid or siRNA. All transfections were performed using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. pSilencer-X, which produces siRNAs targeting HBx, and pSilencer-control as negative control were used. 46 PCH-9/3091 that contains a genome-length HBV sequence has been described. 47 siRNA duplexes target human mRNAs of Lin28A, Sp-1, Lin28B and c-Myc were synthesized and purified by RiboBio (Guangzhou, China). siRNA duplexes with nonspecific sequences were used as siRNA negative control. The siRNA duplex sequences are all listed in Supplementary Table 1. For qRT-PCR or western blot assay, 1 mg pCMV-X, 2 mg pCMV-X or 2 mg pCMV-tag2B (1 mg pSilencer-X, 2 mg pSilencer-X or 2 mg pSilencer-control) or 1 mg pCH-9/ 3091 plasmid were transfected into cells.
Quantitative reverse transcriptase-PCR
Total RNA of cells (or liver tissues from p21-HBx transgenic mice and patient tissues) were extracted using Trizol reagent (Invitrogen). To examine the expression, real-time PCR was performed by a Bio-Rad (Bio-Rad, Hercules, CA, USA) sequence detection system according to the manufacturer's instructions using double-stranded DNA-specific SYBR Premix Ex TaqTM II Kit (TaKaRa Bio, Dalian, China). Double-stranded DNA specific expression was tested by the comparative Ct method using 2 À DDCt . 48 Primers used are listed in Supplementary Table 1 .
Western blot analysis
The western blot protocol was described previously. 6, 49 Primary antibodies used were rabbit anti-Lin28A (11724-1-AP; Proteintech Group), rabbit antiOct-4 (11263-1-AP; Proteintech Group), rabbit anti-HBx (ab39716; Abcam, Cambridge, UK), rabbit anti-Sp-1 (5407-1, Epitomics, Burlingame, CA, USA), rabbit anti-Lin28B (sc-130802; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and mouse anti-b-actin (A5441, Sigma-Aldrich, St Louis, MO, USA). All experiments were repeated three times.
Construction of the human Lin28A and Lin28B promoter The 5 0 -flanking region (from À 1104 to þ 375 nt ) of Lin28 was amplified by PCR from the genomic DNA of HepG2 using specific primers and was inserted into the XhoI/HindIII site, the upstream of the luciferase gene in the pGL3-basic vector (Promega, Madison, WI, USA). The resulting plasmid was sequenced and named pGL3-Lin28A-P1. To construct various lengths of luciferase reporter plasmids of Lin28A, the regions ( À 643/ þ 375, À 235/ þ 375, À 66/ þ 375, þ 152/ þ 375) of Lin28A were amplified by PCR from the pGL3-Lin28A-P1 using specific primers and were inserted into the pGL3-basic vector, named pGL3-Lin28A-P2, pGL3-Lin28A-P3, pGL3-Lin28A-P4 and pGL3-Lin28A-P5, respectively. Mutant construct of pGL3-Lin28A-P3, named as pGL3-Lin28A-P3-MUT, which carried a substitution of four nucleotides within the binding sites of Sp-1, was carried out using overlapping extension PCR. All primers are listed in Supplementary Table 1 . The promoter region ( À 266/ þ 1403) of Lin28B was inserted into the KpnI/ XhoI site, upstream of the luciferase gene in the pGL3-Basic vector (Promega). The resulting plasmid was named pGL3-Lin28B-P. Primers used are listed in Supplementary Table 1. Luciferase reporter gene assay Cells were transferred into 24-well plates at 3 Â 10 4 cells per well. After 24 h, the cells were transiently co-transfected with the pRL-TK plasmid (Promega) containing the Renilla luciferase gene, which is used for internal normalization, and various constructs containing different lengths of the Lin28A and Lin28B 5 0 -flanking region or pGL3-Basic. Cells were harvested and lysed in 1 Â passive lysis buffer after 48 h. The luciferase activity was determined by using the Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's instructions. All experiments were performed at least three times.
Co-immunoprecipitation
The HepG2-X cells were washed three times with phosphate-buffered saline and then lysed in lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.5% (v/v) Nonidet P-40 and 1 mM EDTA) with protease inhibitor cocktail. Protein extracts were incubated with anti-HBx or anti-Sp-1 antibody and protein-G sepharose beads overnight at 4 1C. Immunoglobulin G was used as negative control. The immunoprecipitates were washed 10 times with the same buffer, and then analyzed by SDS-polyacrylamide gel electrophoresis and visualized by immunoblotting with antibodies against HBx or Sp-1.
Chromatin immunoprecipitation
To investigate whether HBx protein is able to bind to the promoter region of Lin28A, we performed ChIP assays according to the manufacturer's protocol (Epigentek Group Inc., Brooklyn, NY, USA) as reported previously. 50, 51 Electrophoretic mobility shift assay The EMSA protocol was described previously. 52 Nuclear extracts were prepared from HepG2 and HepG2-X cells. Probes were generated by annealing single-strand oligonucleotides containing the Sp-1 consensus sequence ( À 100/ À 58) of Lin28A promoter and labeling the ends with HBx promotes proliferation via Lin28A and Lin28B X You et al [g-32 P]ATP using T4 polynucleotide kinase (TaKaRa Bio). The oligonucleotide sequences ( À 100/ À 58) are listed in Supplementary  Table 1 . EMSA was performed with 1 mg of nuclear extract in binding buffer (20 mM Hepes, pH 7.9, 0.05 mM EDTA, pH 8.0, 50 mM KCl, 1 mM MgCl 2 , 0.5 mM dithiothreitol and 5% glycerol) containing 1 mg of poly(deoxyinosinicdeoxycytidylic) acid . A total of 1 mg anti-HBx antibody (Abcam), anti-Sp-1 antibody (Epitomics), immunoglobulin G or 10-fold competitors were incubated with nuclear extracts on ice for 30 min before probes were added into the binding buffer. Samples were incubated on ice for 1 h and then separated by electrophoresis on 6% nondenaturing polyacrylamide gel, and then the gel was dried and subjected to autoradiography.
Analysis of cell proliferation
For quantitative proliferation assays, HepG2/HepG2-X or H7402/H7402-X cells were seeded onto 96-well plates (1000 cells/well) for 24 h before transfection and MTT (Sigma, St Louis, MO, USA) assays were used to assess cell proliferation every day from the first day until the third day after transfection. The protocol was described previously. 6 The EdU incorporation assay was carried out using the Cell-Light TM EdU imaging detecting kit according to the manufacturer's instructions (RiboBio).
Analysis of colony formation
For clonogenicity analysis, at 48 h after transfection, 1000 viable transfected cells were placed in 6-well plates and maintained in complete medium for 2 weeks. Colonies were fixed with methanol and stained with methylene blue.
Animal transplantation
Nude mice were housed and treated according to the guidelines established by the National Institutes of Health Guide for the Care and Use of Laboratory Animals. We conducted animal transplantation according to the Declaration of Helsinki Principles. Briefly, 24 h after transfection with 60 nM siRNA, the Lin28A siRNA1 (or Lin28B siRNA)-pretreated cells or control siRNA-pretreated cells were harvested and re-suspended at 2 Â 10 7 per ml with sterile phosphate-buffered saline. Groups of 4-week-old female BALB/c athymic nude mice (Experiment Animal Center of Peking, China) (each group, n ¼ 6) were subcutaneously injected at the shoulder with 0.2 ml of the cell suspensions. Tumor growth was measured after 10 days from injection and then every 5 days. Tumor volume (V) was monitored by measuring the length (L) and width (W) with calipers and calculated with the formula (L Â W 2 ) Â 0.5. After 30 days, tumor-bearing mice and controls were killed, and the tumors were excised and measured.
Statistical analysis
Each experiment was repeated at least three times. Statistical significance was assessed by comparing mean values (±s.d.) using Student's t-test for independent groups and was assumed for *Po0.05,**Po0.01 and ***Po0.001. Association between expression levels of Lin28A/Lin28B and HBx in tumorous tissues was explored using Pearson's correlation coefficient. Lin28A and Lin28B expression in primary HCC tissues and corresponding nontumorous livers were compared using Wilcoxon's signed-rank test.
